This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Clomipramine Collaborative Study Group

Arch Gen Psychiatry. 1991;48(8):730-738.

Abstract
• Two double-blind studies at 21 centers evaluated the therapeutic efficacy, safety, and tolerability of up to 300 mg/d of clomipramine hydrochloride or an equivalent number of placebo capsules in the treatment of 520 patients with obsessive-compulsive disorder, of whom 239 had had the disorder for at least 2 years (study 1) and 281 had been ill for at least 1 year (study 2). On the two principal measures of the severity of the disorder, ie, the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global Obsessive Compulsive Scale, clomipramine was significantly more effective than placebo in both studies. The mean reduction in the Yale-Brown Obsessive Compulsive Scale score at the end of 10 weeks of treatment was 38% and 44% in studies 1 and 2, respectively, for the clomipramine-treated patients and 3% and 5% for the placebotreated patients. The drug was also found to be superior on the basis of the physicians' and patients' evaluations of global therapeutic change. The most frequently observed adverse effects during clomipramine therapy were those typically associated with tricyclic antidepressant drugs. Although uncommon, the occurrence of seizures and elevated aminotransferase values are potentially serious side effects of clomipramine. Clomipramine was generally well tolerated and was effective in reducing obsessive and compulsive symptoms.

Author Affiliations
Members of The Clomipramine Collaborative Study Group are listed in a box on this page.

Footnotes
Accepted for publication October 15, 1990.

Reprint requests to Clinical Neuropharmacology, Glaxo Inc, 5 Moore Dr, Research Triangle Park, NC 27709 (Joseph DeVeaugh Geiss, MD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder
Foa et al.
Focus 2007;5:368-380.
ABSTRACT | FULL TEXT  

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder
Foa et al.
Am. J. Psychiatry 2005;162:151-161.
ABSTRACT | FULL TEXT  

A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Kaplan and Hollander
Focus 2004;2:454-461.
ABSTRACT | FULL TEXT  

Behavioral Versus Pharmacological Treatments of Obsessive Compulsive Disorder: A Meta-Analysis
Kobak et al.
Focus 2004;2:462-474.
ABSTRACT | FULL TEXT  

A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Kaplan and Hollander
Psychiatr. Serv. 2003;54:1111-1118.
ABSTRACT | FULL TEXT  

Dr. Goldsmith and Colleagues Reply
GOLDSMITH et al.
Am. J. Psychiatry 2000;157:839--839.
FULL TEXT  

Multicenter Double-blind Comparison of Sertraline and Desipramine for Concurrent Obsessive-Compulsive and Major Depressive Disorders
Hoehn-Saric et al.
Arch Gen Psychiatry 2000;57:76-82.
ABSTRACT | FULL TEXT  

Intravenous Clomipramine for Obsessive-Compulsive Disorder Refractory to Oral Clomipramine: A Placebo-Controlled Study
Fallon et al.
Arch Gen Psychiatry 1998;55:918-924.
ABSTRACT | FULL TEXT  

The Partial Responder to Antipsychotic Medications: Putting the Pieces together
Molloy
J Am Psychiatr Nurses Assoc 1998;4:S10-S17.
ABSTRACT  

Is Olfactory Reference Syndrome an Obsessive-Compulsive Spectrum Disorder?: Two Cases and a Discussion
Stein et al.
J. Neuropsychiatry Clin. Neurosi. 1998;10:96-99.
ABSTRACT | FULL TEXT  

Advances in the Psychosocial Treatment of Anxiety Disorders: Implications for National Health Care
Barlow and Lehman
Arch Gen Psychiatry 1996;53:727-735.
ABSTRACT  

Hoarding and Obsessive-Compulsive Symptoms
Frost et al.
Behav Modif 1996;20:116-132.
ABSTRACT  

Selective serotonin reuptake inhibitors in obsessive-compulsive disorder
DTB 1995;33:47-48.
ABSTRACT | FULL TEXT  

Cingulotomy for Intractable Obsessive-compulsive Disorder: Prospective Long-term Follow-up of 18 Patients
Baer et al.
Arch Gen Psychiatry 1995;52:384-392.
ABSTRACT  

Double-blind Parallel Comparison of Three Dosages of Sertraline and Placebo in Outpatients With Obsessive-compulsive Disorder
Greist et al.
Arch Gen Psychiatry 1995;52:289-295.
ABSTRACT  

Efficacy and Tolerability of Serotonin Transport Inhibitors in Obsessive-compulsive Disorder: A Meta-analysis
Greist et al.
Arch Gen Psychiatry 1995;52:53-60.
ABSTRACT  

A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder
Tollefson et al.
Arch Gen Psychiatry 1994;51:559-567.
ABSTRACT  

Tryptophan Depletion in Patients With Obsessive-Compulsive Disorder Who Respond to Serotonin Reuptake Inhibitors
Barr et al.
Arch Gen Psychiatry 1994;51:309-317.
ABSTRACT  

Effect of Axis II Diagnoses on Treatment Outcome With Clomipramine in 55 Patients With Obsessive-Compulsive Disorder
Baer et al.
Arch Gen Psychiatry 1992;49:862-866.
ABSTRACT  

Caudate Glucose Metabolic Rate Changes With Both Drug and Behavior Therapy for Obsessive-Compulsive Disorder
Baxter et al.
Arch Gen Psychiatry 1992;49:681-689.
ABSTRACT  

Psychiatry
Freedman and Stahl
JAMA 1992;268:403-405.
ABSTRACT  

A Family Study of Obsessive-Compulsive Disorder
Black et al.
Arch Gen Psychiatry 1992;49:362-368.
ABSTRACT  

Academic Medical Center/Industry Collaboration
DeVeaugh-Geiss
Arch Gen Psychiatry 1991;48:754-756.
ABSTRACT